达格列净减少凝血酶生成与血小板活化:对2型糖尿病心血管风险降低的意义
本研究在Ldlr-/-小鼠和健康志愿者中探讨达格列净对血小板-炎症交互作用的影响。达格列净改善动脉粥样硬化病变,减少血小板-白细胞聚集体和主动脉巨噬细胞浸润,降低活化血小板比例和凝血酶生成,并升高HDL胆固醇,且不影响出血时间。在人体中,达格列净降低胶原相关肽或TRAP-6刺激后的CD62P阳性血小板比例,不干扰止血。
要点
- 达格列净减少小鼠动脉粥样硬化病变、血小板-白细胞聚集体和主动脉巨噬细胞浸润。
- 达格列净降低小鼠和人体活化血小板比例及凝血酶生成,不延长出血时间。
- HDL胆固醇升高可能介导达格列净的抗血小板和抗凝血酶生成效应。
核心结论
- 达格列净通过升高HDL胆固醇和改善凝血酶-血小板介导的炎症发挥小鼠抗动脉粥样硬化作用,且不干扰止血。
研究设计与样本
- 雄性8周龄Ldlr-/-小鼠接受高脂高蔗糖致糖尿病饮食,分为对照组和达格列净5 mg/kg/天组,干预8周和25周。
- 8名健康志愿者接受达格列净10 mg/天共4周。
主要发现
- 达格列净减少循环血小板-白细胞聚集体(GPIb+CD45+:29.40 ± 5.94 vs 17.00 ± 5.69 cells,p < 0.01;GPIb+Ly6G+:8.00 ± 2.45 vs 4.33 ± 1.75 cells,p < 0.05)。
- 达格列净减少主动脉巨噬细胞浸润(1.31 ± 0.62 vs 0.70 ± 0.58 ×10^3 cells/aorta,p < 0.01)。
- 达格列净降低小鼠活化CD62P阳性血小板比例(3.78 ± 1.20% vs 2.83 ± 1.06%,p < 0.01),出血时间无显著变化(85.29 ± 37.27 vs 89.25 ± 16.26 s,p = 0.78)。
- 达格列净降低内源性凝血酶生成(581.4 ± 194.6 vs 254.1 ± 106.4 (nmol/l × min) × 10^-9 thrombin)。
- 达格列净升高HDL胆固醇(1.70 ± 0.58 vs 3.15 ± 1.67 mmol/l,p < 0.01);人体中降低CRP刺激后CD62P阳性血小板比例(88.13 ± 5.37% vs 77.59 ± 10.70%,p < 0.05)和TRAP-6刺激后比例(44.23 ± 15.54% vs 28.96 ± 11.41%,p < 0.01),不干扰止血。
临床怎么用
- 达格列净可能通过不依赖降糖的抗血小板和抗凝血酶生成机制降低2型糖尿病心血管风险。
- 达格列净的抗动脉粥样硬化效应可能部分由HDL胆固醇升高介导,且不增加出血风险。
局限性
- 动物实验采用Ldlr-/-小鼠高脂高蔗糖饮食模型,人体研究仅8名健康志愿者且干预4周,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: People with diabetes have an increased cardiovascular risk with an accelerated development of atherosclerosis and an elevated mortality rate after myocardial infarction. Therefore, cardioprotective effects of glucose-lowering therapies are of major importance for the pharmacotherapy of individuals with type 2 diabetes. For sodium-glucose cotransporter 2 inhibitors (SGLT2is), in addition to a reduction in blood glucose, beneficial effects on atherosclerosis, obesity, renal function and blood pressure have been observed. Recent results showed a reduced risk of worsening heart failure and cardiovascular deaths under dapagliflozin treatment irrespective of the diabetic state. However, the underlying mechanisms are yet unknown. Platelets are known drivers of atherosclerosis and atherothrombosis and disturbed platelet activation has also been suggested to occur in type 2 diabetes. Therefore, the present study investigates the impact of the SGLT2i dapagliflozin on the interplay between platelets and inflammation in atherogenesis. METHODS: Male, 8-week-old LDL-receptor-deficient (Ldlr-/-) mice received a high-fat, high-sucrose diabetogenic diet supplemented without (control) or with dapagliflozin (5 mg/kg body weight per day) for two time periods: 8 and 25 weeks. In a first translational approach, eight healthy volunteers received 10 mg dapagliflozin/day for 4 weeks. RESULTS: Dapagliflozin treatment ameliorated atherosclerotic lesion development, reduced circulating platelet-leucocyte aggregates (glycoprotein [GP]Ib+CD45+: 29.40 ± 5.94 vs 17.00 ± 5.69 cells, p < 0.01; GPIb+lymphocyte antigen 6 complex, locus G+ (Ly6G): 8.00 ± 2.45 vs 4.33 ± 1.75 cells, p < 0.05) and decreased aortic macrophage infiltration (1.31 ± 0.62 vs 0.70 ± 0.58 ×103 cells/aorta, p < 0.01). Deeper analysis revealed that dapagliflozin decreased activated CD62P-positive platelets in Ldlr-/- mice fed a diabetogenic diet (3.78 ± 1.20% vs 2.83 ± 1.06%, p < 0.01) without affecting bleeding time (85.29 ± 37.27 vs 89.25 ± 16.26 s, p = 0.78). While blood glucose was only moderately affected, dapagliflozin further reduced endogenous thrombin generation (581.4 ± 194.6 nmol/l × min) × 10-9 thrombin vs 254.1 ± 106.4 (nmol/l × min) × 10-9 thrombin), thereby decreasing one of the most important platelet activators. We observed a direct inhibitory effect of dapagliflozin on isolated platelets. In addition, dapagliflozin increased HDL-cholesterol levels. Importantly, higher HDL-cholesterol levels (1.70 ± 0.58 vs 3.15 ± 1.67 mmol/l, p < 0.01) likely contribute to dapagliflozin-mediated inhibition of platelet activation and thrombin generation. Accordingly, in line with the results in mice, treatment with dapagliflozin lowered CD62P-positive platelet counts in humans after stimulation by collagen-related peptide (CRP; 88.13 ± 5.37% of platelets vs 77.59 ± 10.70%, p < 0.05) or thrombin receptor activator peptide-6 (TRAP-6; 44.23 ± 15.54% vs 28.96 ± 11.41%, p < 0.01) without affecting haemostasis. CONCLUSIONS/INTERPRETATION: We demonstrate that dapagliflozin-mediated atheroprotection in mice is driven by elevated HDL-cholesterol and ameliorated thrombin-platelet-mediated inflammation without interfering with haemostasis. This glucose-independent mechanism likely contributes to dapagliflozin's beneficial cardiovascular risk profile.
引用
- Kohlmorgen C, Gerfer S, Feldmann K, et al. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia. 2021. PMID: 34131781. doi:10.1007/s00125-021-05498-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。